Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GS 1219

Next Previous
Drug Profile

GS 1219

Alternative Names: GS-1219

Latest Information Update: 03 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 21 Oct 2025 Gilead Sciences terminates a phase I clinical trial in HIV infections in USA (PO) based on sponsor's decision (NCT07115368)
  • 11 Aug 2025 Phase-I clinical trials in HIV infections in USA (PO) (NCT07115368)
  • 11 Aug 2025 Gilead Sciences plans phase I trial for HIV infections in August 2025 (PO) (NCT07115368)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top